Biocept Inc. (BIOC)

0.29
0.01 3.64
NASDAQ : Health Technology
Prev Close 0.30
Open 0.31
Day Low/High 0.28 / 0.31
52 Wk Low/High 0.26 / 2.75
Volume 702.66K
Avg Volume 1.56M
Exchange NASDAQ
Shares Outstanding 63.59M
Market Cap 19.11M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Comments On Updated Consensus Medical Guidelines Recommending Liquid Biopsy For Profiling Of Tumor Biomarkers To Assist With The Treatment Of Patients With Lung Cancer

Biocept Comments On Updated Consensus Medical Guidelines Recommending Liquid Biopsy For Profiling Of Tumor Biomarkers To Assist With The Treatment Of Patients With Lung Cancer

Published medical guidelines influence treatment practices and can drive clinical adoption of emerging technologies designed to improve the treatment of serious or life-threatening diseases

Biocept Obtains Patent In Australia For Its Molecular Biomarker Technology For The Detection Of Cancer-Associated Mutations In Blood, Tissue, And Other Biological Sources

Biocept Obtains Patent In Australia For Its Molecular Biomarker Technology For The Detection Of Cancer-Associated Mutations In Blood, Tissue, And Other Biological Sources

Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)

First U.S. Patent Issued For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Liquid Biopsy CtDNA Platform

First U.S. Patent Issued For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Liquid Biopsy CtDNA Platform

Expands Biocept's intellectual property portfolio to 21 issued patents for its highly sensitive methods of detecting cancer biomarkers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA)

Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

Clinical validation of Biocept's novel PD-L1 test using multiple antibody clones has potential to improve detection, treatment selection, and patient monitoring with cancer immunotherapy

Biocept Launches Pathology Partnership Initiative Expanding Access Of Proprietary Liquid Biopsy Testing To Community Pathologists And Hospitals

Biocept Launches Pathology Partnership Initiative Expanding Access Of Proprietary Liquid Biopsy Testing To Community Pathologists And Hospitals

First and only platform that enables local pathologists to obtain molecular biomarker information from a simple blood sample using cutting-edge circulating tumor cell (CTC) technology

Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board

Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board

Expands Company's advisory board of oncology and academic leaders to eight members

Biocept And Miraca Life Sciences Enter Into Marketing Agreement To Expand Target Selector Testing In The United States

Biocept And Miraca Life Sciences Enter Into Marketing Agreement To Expand Target Selector Testing In The United States

MLS to market Biocept's proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

Biocept Launches Liquid Biopsy Test For NRAS Mutations

Biocept Launches Liquid Biopsy Test For NRAS Mutations

Expands commercial offering to 15 clinically actionable biomarker tests, including key validated alterations listed in the NCCN Guidelines® for metastatic melanoma and colorectal cancer

Biocept And UT Southwestern Medical Center Announce Clinical Study To Profile And Monitor Non-Small Cell Lung Cancer Patients With ALK Rearrangements

Biocept And UT Southwestern Medical Center Announce Clinical Study To Profile And Monitor Non-Small Cell Lung Cancer Patients With ALK Rearrangements

Leading clinical investigator to utilize Biocept's liquid biopsy tests for the detection of ALK rearrangements at baseline and to monitor treatment response and resistance mechanisms over time

Biocept Enters Into Exclusive Distribution Agreement With Global Laboratory Product Supplier VWR

Biocept Enters Into Exclusive Distribution Agreement With Global Laboratory Product Supplier VWR

Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world

Biocept Announces Private Placement Of $2.2 Million Of Common Stock With Ally Bridge LB Healthcare Master Fund

Biocept Announces Private Placement Of $2.2 Million Of Common Stock With Ally Bridge LB Healthcare Master Fund

Biocept and Ally Bridge to evaluate strategic opportunities in China for the Company's liquid biopsy platform

Biocept Executes Preferred Provider Agreement With Scripps Health Plan Expanding Patient Coverage For Its Liquid Biopsy Platform

Biocept Executes Preferred Provider Agreement With Scripps Health Plan Expanding Patient Coverage For Its Liquid Biopsy Platform

Prestigious Southern California health plan contracts with Biocept to make the Company's Target Selector™ tests available in-network for its patients with cancer

Biocept Expands Commercial Offering Of Clinically Actionable Biomarker Assays With Launch Of Liquid Biopsy Test For Progesterone Receptor Detection

Biocept Expands Commercial Offering Of Clinically Actionable Biomarker Assays With Launch Of Liquid Biopsy Test For Progesterone Receptor Detection

Biocept now offers 14 clinically actionable biomarker tests, including all validated biomarkers for breast cancer in NCCN Guidelines®

Biocept Awarded U.S. Patent With Broad Claims For Antibody Capture Of Targets Of Interest On Any Solid Surface Including CTCs And Other Materials Shed By Solid Tumors Into Blood

Company's intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology

Biocept's Target Selector Platform Featured In Three Clinical Abstracts At The 2017 American Society Of Clinical Oncology Annual Meeting Where Company Plans To Launch New Marketing Campaign

Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsy

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

TheStreet Quant Rating: E+ (Sell)